Ilexus Pty Limited

The Macfarlane Burnet Institute for Medical Research and Public Health Limited

Ascend Biopharmaceuticals Ltd

Ascend Biopharmaceuticals Pty Ltd.

Geoffrey Alan Pietersz

Jonathan Bayldon Baell

Barry Ross Matthews

Ian F C McKenzie

Thomas P J Garrett

P Mark Hogarth

Thomas D McCarthy

Vasso Apostolopoulos

Clement Leong

Maree S Powell

Kelly F Maxwell

Vidana Epa

The present invention relates to methods of treating a disease characterised by aberrant cell proliferation (e.g., a cancer) in a human subject in need thereof. In particular, the present invention relates to treating the above conditions by administering a therapeutically effective amount of at least one agent that increases activation of a receptor of at least one type II interferon and/or type I interferon, and administering to the subject at least one agent that inhibits the Hedgehog (Hh) signalling pathway (e.g., Vismodegib). Also provided are pharmaceutical compositions, including controlled release pharmaceutical compositions, containing at least one agent that increases activation of a receptor of at least one type II interferon and/or type I interferon (e.g., a checkpoint inhibitor), an inhibitor of Hh signalling pathway, and a controlled release matrix such as a SiOmatrix gel.

Methods of treatment and related compositions

The present invention provides an immunomodulatory compound comprising a carbohydrate polymer comprising mannose, wherein the carbohydrate polymer is conjugated to at least one immune modulator. The present invention also provides for the use of this compound in immunomodulatory compositions for vaccination and gene therapy methods, together with processes for its preparation.

Immunomodulatory conjugates

The present invention provides an immunostimulatory composition comprising mannans, wherein at least 75% of the mannans are greater than about 1000 kDa and/or have at least 150 aldehyde groups. The present invention also provides for the use of this composition in vaccination and gene therapy methods, together with processes for its preparation.

Use of high molecular weight mannan for inducing and/or enhancing an immune response

The present invention relates to a method of eliciting a cytotoxic T lymphocyte response to an antigen in an animal, the method comprising pulsing mannose receptor-bearing antigen presenting cells in vitro or ex vivo with a conjugate comprising an antigen and a carbohydrate polymer comprising mannose, wherein said carbohydrate polymer is a fully oxidized carbohydrate polymer comprising free aldehydes; and administering the pulsed antigen presenting cells to an animal.

Compositions for immunotherapy and uses thereof

The present invention relates to an immunogenic composition comprising a conjugate between an antigen and an oxidized mannan comprising mannose units and aldehyde groups, and a pharmaceutically acceptable carrier.

This invention relates to a method of inhibiting Fc receptor binding of immunoglobulin including the use of a Fc receptor modulating compound which binds to defined surfaces on a Fc receptor. The present invention also relates to a method for treating a variety of diseases using a Fc receptor modulating compound.

Fc receptor modulators and uses thereof

Methods for inhibiting Fc receptor binding of immunoglobulin in a patient comprising administering pharmaceutical compositions comprising Fc modulating compounds are disclosed.

This invention relates to a pharmaceutical composition comprising a Fc receptor modulating compound and a pharmaceutically acceptable carrier. The present invention also relates to a method for treating a variety of diseases using a Fc receptor modulating compound.

Growing community of inventors

Greensborough, Australia

Geoffrey Alan Pietersz